MS relapse

Multiple sclerosis causes debilitating fatigue. The following photographs show, without censorship, what my fatigue leaves undone. The homes of everyone I know have living rooms without sweaters tossed over the back of chairs. Their floors are not an obstacle course. They do not have piles of mail, notes, drills,…

Many decisions to stop taking the multiple sclerosis treatment Tysabri (natalizumab) appear to be based largely on subjective factors such as patients’ or physicians’ view of the risk, rather than objective assessments of the risk, a study indicates. Tysabri is an approved immunotherapy for active relapsing-remitting multiple sclerosis (RRMS). Despite its benefits, there…

The latest results on Tecfidera (dimethyl fumarate) and Tysabri (natalizumab) use in a clinical practice setting suggest that early treatment can improve outcomes in multiple sclerosis (MS) patients. This and other recent data on Tecfidera and Tysabri for the treatment of MS will be presented by Biogen at the…

While many multiple sclerosis patients celebrated the recent approval of Ocrevus (ocrelizumab), others argued that the drug is largely a rebranded version of rituximab. Rituximab — sold as Rituxan for indications like non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis — is used off-label to treat relapsing MS. In online forums and social media,…

Multiple sclerosis is a very complex disease that attacks the central nervous system. The symptoms MS generates are random, affect everyone differently, and are categorized either as primary MS, or secondary MS, symptoms. Primary MS symptoms are the direct result of the disease itself — byproducts of the damaged…

Here is a transcript of the Multiple Sclerosis News Today interview about Ocrevus (ocrelizumab) with Dr. Robert Lisak of the Consortium of Multiple Sclerosis Centers (CMSC). Lisak, a professor of neurology and of immunology and microbiology at Wayne State University School of Medicine, is a former…

Thirteen years ago, a neurologist sat on the edge of my hospital bed and told me, “You have MS. It’s not the end of the world. There’s more on the internet than I could ever tell you about, so I suggest you do some research. Good night.” Since…

What is benign MS? Does it even exist? Certainly it is not one of the types of the disease often listed as making up the multiple sclerosis family. It is a term that is surrounded by controversy,…

The 2017 version of MuckFest MS, the five-kilometer fundraising mud-run series, will begin in a few weeks. The event, organized by the National Multiple Sclerosis Society and Event 360, features more than 18 obstacles in muddy settings. They include the swing set, muck off, skid mark, and more. Participants…

Relaxation and serenity are both attainable with the correct calming techniques. When overwhelmed by stress, the skills that have been gained and practiced become second nature to be summoned as needed. The combination of stress and multiple sclerosis can wreak havoc in the body. It can lead to a…

The United Kingdom’s National Institute for Health and Care Excellence (NICE) has cleared its initial doubts and now recommends Zinbryta (daclizumab) to treat relapsing multiple sclerosis (MS) in England and Wales. NICE had initially rejected Zinbryta after a first stage of the drug’s review process, due to some issues linked to…

News that daclizumab, brand name Zinbryta, has been given the go-ahead to be available through the U.K.’s National Health Service (NHS) for treating relapsing MS, at least in part of the country, is good news. But why has the decision taken…

When describing a multiple sclerosis exacerbation (also called a relapse, attack, or flare-up), comparing it to a home’s circuit panel is a good analogy to use. When a fuse blows on the circuit board the power is interrupted. During an MS attack, the myelin sheath that covers nerve axons…

A number of multiple sclerosis organizations have joined Biogen in the second year of the #MySupportHero initiative. The social media campaign is a way for people with multiple sclerosis (MS)  to thank those who give them the care,  encouragement, attention, and strength they need. The initiative runs through the end of March, which…

March is recognized by the Multiple Sclerosis Association of America as MS Awareness Month. Awareness is a vital component of any illness. We must actively engage to collectively congregate and support the cause by way of our time, resources and voices. We are seeking to make communities aware of…

Ten years after completing treatment with Novantrone (mitoxantrone), a chemotherapy drug, multiple sclerosis (MS) patients showed evidence of markedly lower annualized relapse rates, but the therapy’s effects began to wane after five years, a study presented at ACTRIMS 2017 Forum reported. The study also assessed how Novantrone affects disease progression in primary and secondary progressive…

Editor’s note: Columnist Laura Kolaczkowski reports from ACTRIMS in Orlando, Fla. The second Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) got under way in Orlando, Fla., today and runs through Saturday. I have the honor of being on site to hear  presentations…

Treatment with Apitope’s lead agent, ATX-MS-1467, decreased brain lesions in patients with relapsing multiple sclerosis (MS) in a now-completed Phase 2a clinical trial. ATX-MS-1467 is a potential disease-modifying agent with an immune-tolerating action. It consists of four short peptides derived from the myelin basic protein, and is designed to reduce…

Fatigue is the bane of my existence. Clutter qualifies as my lifestyle. If I can’t see something it may as well be lost. I spend about 50% of my day trying to find things I have put “someplace safe.” The other half I spend looking for something I just had…

A Phase 3 clinical trial evaluating the safety and effectiveness of ozanimod (RPC-1063) in patients with relapsing multiple sclerosis (RMS) shows treatment reduced the disease’s annualized relapse rate (ARR), researchers reported. The Phase 3 SUNBEAM trial (NCT02294058) tested ozanimod, an oral, selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator designed to…

The second annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), a forum for clinicians, researchers and other MS specialists to network and discuss the  latest advances in MS research and treatment is set for Feb. 23–25. This year’s meeting takes place at the Omni ChampionsGate resort hotel in Orlando, Florida. Multiple Sclerosis News…

EMD Soreno has recently published Phase 3 clinical data showing that Cladribine tablets reduced the annualized rate of brain volume loss (BVL, brain atrophy) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS). The study, “Reduced brain atrophy rates are associated with lower risk of disability progression…

Switching from Gilenya (fingolimod) to Lemtrada (alemtuzumab) triggers significant and unexpected disease activity in some patients with multiple sclerosis (MS), according to a study published in the scientific journal Neurology Neuroimmunology and Neuroinflammation.

Continuous treatment with Gilenya (fingolimod) helps limit relapses and detectable lesions in multiple sclerosis (MS) patients, according to a three-year, follow-up study in Japan. The results confirm the findings of trials conducted in predominantly Caucasian populations. The findings were reported in the study, “Long-term efficacy and safety of fingolimod in…

Recent weeks have been filled with enough political drama to last a lifetime. Wherever I go virtually (and now, even in “real life”), ideological division has been amplified to the extreme. Except … when I go to the multiple sclerosis online forum I co-administrate. Meet the people in my neighborhood The…

Many multiple sclerosis (MS) patients have a reduced sense of smell, and the more relapses they have, the worse the problem, according to a study suggesting that smell may be a marker for the disease’s progression. Findings also suggested a connection between reduced sense of taste and MS progression. The…

Early data from TG Therapeutics’ Phase 2 trial of its B-cell-targeting experimental multiple sclerosis (MS) treatment ublituximab (TG-1101), showed that the drug is well-tolerated and effectively reduces B-cells in the blood. MS therapies that deplete B-cells have been effective in relapsing and progressive forms of MS. Like other B-cell-targeting drugs in…

Researchers have identified two factors that allow Th17 cells —  which drive multiple sclerosis (MS) and other autoimmune conditions — to form memory cells in the body and cause repeated symptom flare-ups. Knowing the identity of the molecules, which are immune mediators called cytokines, will make it possible for scientists to search…

As I was looking down typing one of my articles recently, I experienced a unique pain in my neck. It was one I haven’t felt before. It was a sharp electrifying pain that started on the left side of my neck, and propelled itself on a downward zig-zagging path…

Here’s my Pick of the Week’s News, as published by Multiple Sclerosis News Today. Inactivity and Poor Diet Are Common Risk Factors Among MS Patients, Study Says For years, people with MS have been advised to exercise more and eat healthy foods. That is advice given to…